News for Healthier Living

Cardiometabolic Outcomes Improve with Greater Weight Reduction Among Tirzepatide Users

A post-hoc analysis of the phase 3, randomized, double-blind, SURMOUNT-1 trial aimed to determine changes in cardiometabolic risk factors by degree of weight reduction in adults with obesity or overweight treated with tirzepatide.

June 23, 2025


June 23 2025

June 22 2025

June 21 2025

June 20 2025

June 19 2025

June 18 2025

June 17 2025

June 16 2025

June 15 2025

June 14 2025

June 13 2025

June 12 2025

June 11 2025

June 10 2025

June 9 2025